

FIG. 1

Antibody Name	amidolytic activity [10nM Ig] absorption 405nm raw data	amidolytic activity [2nM Ig] raw data slope AU 405nm /min	VH/VL Combination	normalized amidolytic activity @ 10 nM Ig/ [AU/mM Ig]	normalized amidolytic activity @ 2 nM Ig / [AU/mM Ig]	Binding to hPC (SPR) / KD [nM]	Tagg UNCLE [°C]	UNCLE remark	μ-scale express. [μg/ml]	stdev
TPP-26870	0.00902	0.00746	AL14542VH-AL14715VL	0.455	1.582	no binding	68.2	OK	139	11
TPP-26926	0.00916	0.00822	AL14545VH-AL14651VL	0.469	1.962	no binding	71.7	OK	184	11
TPP-26862	0.00869	0.00704	AL14542VH-AL14667VL	0.422	1.372	no binding	66.9	OK	59	11
TPP-26894	0.00808	0.00571	AL14544VH-AL14723VL	0.360	0.707	no binding	67.6	OK	63	4
TPP-26863	0.00795	0.00684	AL14542VH-AL14675VL	0.348	1.272	no binding	65.7	OK	34	5
TPP-26864	0.00706	0.00641	AL14542VH-AL14707VL	0.258	1.058	no binding	68.3	OK	58	6
TPP-26869	0.00862	0.0086	AL14542VH-AL14713VL	0.414	2.153	no binding	68.4	OK	164	30
TPP-26918	0.00842	0.00749	AL14545VH-AL14635VL	0.395	1.598	no binding	71.7	OK	166	5
TPP-26925	0.00862	0.00789	AL14545VH-AL14659VL	0.414	1.797	no binding	72.9	OK	123	10
TPP-26882	0.00767	0.00628	AL14543VH-AL14713VL	0.319	0.993	no binding	74.5	OK	178	14
TPP-26873	0.00809	0.0069	AL14542VH-AL14659VL	0.362	1.302	no binding	68.6	OK	127	5
TPP-26872	0.00782	0.00685	AL14542VH-AL14657VL	0.335	1.278	no binding	69.1	OK	87	4
TPP-26874	0.00843	0.00805	AL14542VH-AL14651VL	0.395	1.878	no binding	68.0	OK	170	12
TPP-26871	0.00802	0.00776	AL14542VH-AL14649VL	0.355	1.733	no binding	69.8	OK	162	19
TPP-26935	0.00842	0.00778	AL14549VH-AL14715VL	0.394	1.742	no binding	65.5	OK	90	18
TPP-24727	0.0078	0.00618	AL5992VH-AL5991VL	0.333	0.942	no binding	67.4	OK	69	13
TPP-26934	0.0091	0.00785	AL14549VH-AL14713VL	0.462	1.777	no binding	65.1	OK	149	40
TPP-26924	0.0077	0.0066	AL14545VH-AL14657VL	0.323	1.153	no binding	72.6	OK	102	4
TPP-26920	0.00839	0.00723	AL14545VH-AL14723VL	0.391	1.468	no binding	70.7	OK	85	12
TPP-26921	0.00821	0.00774	AL14545VH-AL14713VL	0.373	1.723	no binding	70.2	OK	161	7

FIG. 2

Antibody	ka [1/Ms] = kon	kd [1/s]	Binding to hAPC (SPR) / KD [nM]
TPP-26870	1060000	0.0138	12.9
TPP-26926	534000	0.0163	30.5
TPP-26862	1580000	0.0213	13.5
TPP-26894	1940000	0.275	142
TPP-26863	1510000	0.0169	11.2
TPP-26864	1210000	0.0107	8.79
TPP-26869	1080000	0.0147	13.5
TPP-26918	613000	0.00818	13.4
TPP-26925	537000	0.015	27.9
TPP-26882	902000	0.152	169
TPP-26873	1090000	0.0121	11.2
TPP-26872	1160000	0.0148	12.8
TPP-26874	992000	0.0131	13.2
TPP-26871	1030000	0.0142	13.8
TPP-26935	562000	0.010	18.6
TPP-24727	505000	0.00942	18.7
TPP-26934	518000	0.010	19.8
TPP-26924	578000	0.0159	27.5
TPP-26920	679000	0.0191	28.1
TPP-26921	594000	0.0185	31.1


FIG. 3

	Exp. Titer large scale	Purity & Homogeneity			Thermal Stability DSC; Tm [°C] CH2+CH3 / fab	max tested concentration for solubility			Preliminary formulation
		SEC % monomer	cGe % non reduced	cGe % LC + HC reduced		mg/ml; UV/vis	SEC Δ% monomer	cGe Δ% LC + HC	
TPP-24727					69-70 / 69-70				Buffer
TPP-26870	62.3	100	95.8	99.8	69-70 / 73.1	199 (91% recovery)	< 1	< 1	DPBS pH7.4
TPP-26882	332	99.9	95.3	100	69-70 / 82.0	210 (88% recovery)	< 1	< 1	DPBS pH7.4
TPP-26862	31 13	99.9	96.1	100	69-70 / 70.1	189 (87% recovery)	< 1	< 1	DPBS pH7.4
TPP-26926	180	99.7	94.7	99.7	69-70 / 75.4	216 (88% recovery)	< 1	< 1	DPBS pH7.4

FIG. 4


Antibody	normalized amidolytic activity @ 8 nM IgG / [AU/mM IgG]	normalized amidolytic activity @ 3.2 nM IgG / [AU/mM IgG]
TPP-26870	0.958	1.770
TPP-26926	0.998	1.473
TPP-26862	0.911	1.543
TPP-26894	0.436	0.527
TPP-26863	0.736	0.855
TPP-26864	0.630	0.863
TPP-26869	0.711	1.020
TPP-26918	0.686	0.973
TPP-26925	0.905	1.363
TPP-26882	0.514	0.832
TPP-26873	0.758	1.074
TPP-26872	0.811	1.105
TPP-26874	0.773	1.105
TPP-26871	0.755	1.215
TPP-26935	0.952	1.504
TPP-24727	0.730	1.191
TPP-26934	0.955	1.582
TPP-26920	0.677	0.863
TPP-26921	0.736	0.941

FIG. 5




	EC50 (nM)
TPP-24727	3.03
TPP-26870	2.24
TPP-26882	39.7
TPP-26926	4.09
TPP-26862	3.47

FIG. 5 (continued)



	EC50 (nM)
TPP-24727	2.73
TPP-26869	2.82
TPP-26871	3.98
TPP-26873	1.84
TPP-26874	1.80
TPP-26918	2.23

FIG. 5 (continued)



	EC50 (nM)
TPP-24727	2.73
TPP-26920	1.26
TPP-26921	7.05
TPP-26924	>1000
TPP-26925	3.33
TPP-26934	4.32
TPP-26935	5.90

FIG. 6A




FIG. 6B




FIG. 6C

	Screen 1		Screen 2	
	10 nM	30 nM	10 nM	30 nM
TPP-26870	112.1	82.35	113.05	85
TPP-26926	130.35	92.45	131.25	95.35
TPP-26882	190.85	141.4	195.35	147.25
TPP-26862	138.15	101.85	155.2	114.6
TPP-24727	137.4	97.6	140.9	101.25
TPP-26863	152.8	107	154.85	115.05
TPP-26864	132.35	92.75	133.65	97.8
TPP-26869	143.8	99.85	142.4	100.5
TPP-26871	148.4	102.9	151.05	110.35
TPP-26872	146.25	102.65	146.8	107.75
TPP-26873	129.5	91.7	131.25	95.8
TPP-26874	130.05	91.4	138.25	97.85
TPP-26894	188.15	139.05	190.6	143.35
TPP-26918	129.05	93.2	128.6	96.25
TPP-26920	133.05	93.6	126.05	91.8
TPP-26921	166	114.15	159.1	112.3
TPP-26924	275.55	258.4	263.4	256.45
TPP-26925	139.3	98.05	144.15	102.2
TPP-26934	147.3	96.25	152.95	103.9
TPP-26935	128.05	84.4	126.6	85.35
No IgG	261.8	264.05	256.55	258.2
No Protac	41	41	40.8	40.8




FIG. 6E




FIG. 7

Antibody	%SEAP-PAR1 Cleaved 10 Antibody:1 APC (mol/mol)
TPP26870	33.636
TPP26926	39.579
TPP26874	20.22
TPP26918	7.812
TPP26920	18.754
TPP26935	24.700
TPP26863	5.393
TPP26869	32.996
TPP26871	30.615
TPP26872	10.254
TPP26894	12.406
TPP26921	14.294
TPP26924	106.317
TPP26925	9.410
TPP26934	13.016
TPP26862	5.506
TPP26882	15.254
TPP24727 (ref)	13.228

FIG. 8A




FIG. 8B

Antibody (n=2)	Plateau Barrier Protection (%)	SD	Significance (t-test vs TPP24727)	Significance (ANOVA with Dunnnett)
TPP26870	29.9	15.6	P=0.0484	Ns
TPP26926	51.3	7.9	P=0.0002	P=0.0038
TPP26873	34.3	21.7	ns (P=0.0675)	Ns (P=0.13)
TPP26874	17.2	12.7	ns	ns
TPP26918	19.3	21.1	ns	ns
TPP26920	10.1	13.5	ns	ns
TPP26935	44.0	13.8	P=0.0036	P=0.019
TPP24727	9.2	61.	-	-

FIG. 9A






FIG. 9B

Histone 3 Cleavage
(1 APC: 10 Antibody Ratio)



	H3 Band Intensity	
	0 min	60 min
TPP26863	26821.7	50428
TPP26869	28259.5	11970.7
TPP26871	28146.6	132151.5
TPP26872	28896.6	13000
TPP26894	29931.0	15827.6
TPP26921	33034.5	24069.0
TPP26924	282574.3	112216.7
TPP26925	29167.6	18684.0
TPP26934	306478.5	16120.3
TPP26862	32167.8	26862.33
TPP26882	323636.5	18479.1
No Ab	29206.8	187626.3
TPP24727	25255.3	4429.4

FIG. 9C



Ab	APC: Antibody Ratio				
	No APC	1:0	1:0.3	1:1	1:10
TPP26870	255063.7	169172.7	191329.3	193694	181980.7
TPP26926	255063.7	169172.7	209047	204369.3	203141.3
TPP26873	255063.7	169172.7	202836.3	201049.7	180088
TPP26874	275654.8	181495.8	228521	225733	198680.3
TPP26918	275654.8	181495.8	218520	225838	199436
TPP26920	275654.8	181495.8	204557.3	201350	186666
TPP26935	265472.2	171337.7	208011.3	205640.3	202346.7

FIG. 10

Ab	T1/2 (minutes; mean)	SD	P value vs No Antibody
No Antibody 1	29.4	3	ref
No Antibody 2	31.1	3.2	ref
TPP26862	93.9	15.9	<0.0001
TPP26863	nd	nd	nd
TPP26869	101.6	9	<0.0001
TPP26870	110.8	21.9	0.0006
TPP26871	111	19.3	<0.0001
TPP26872	121	12.4	<0.0001
TPP26873	nd	nd	nd
TPP26874	107.6	2.3	0.0009
TPP26882	135.7	35.4	<0.0001
TPP26894	91.5	4.2	<0.0001
TPP26918	196	14.8	<0.0001
TPP26920	198.4	10	<0.0001
TPP26921	92.4	4.7	<0.0001
TPP26924	29.8	0.6	0.9999
TPP26925	105.7	15.8	<0.0001
TPP26926	98.7	9	0.0033
TPP26934	84	4.3	<0.0001
TPP26935	86.4	1.2	0.0193
TPP24727	129.2	1.2	<0.0001

FIG. 11

Antibody	VH Mutation	VL Mutation
TPP-26922		
TPP-26939		
Variants of TPP-26870	TPP-29843	S53T
	TPP-29844	N31I
	TPP-29845	Y32F
	TPP-29846	N31P
	TPP-29847	Y100F
	TPP-29848	Q27E
	TPP-29849	S56W
	TPP-29850	N57W
	TPP-29851	N35S
	TPP-29852	N31F
	TPP-29853	F103M
	TPP-29854	A55K
	TPP-29855	S54R
	TPP-29856	N57H
	TPP-29857	Y100W
	TPP-29858	S56R
	TPP-29860	Q93T
	TPP-29861	S56R
	TPP-29863	S28R
	TPP-29864	N57R
	TPP-29865	M34F
	TPP-29866	T57P

FIG. 12

Antibody	ka (1/Ms)	kd (1/s)	Binding to hAPC (SPR) / KD [nM]	Binding to hPC (@2mM hPC)	normalized amidolytic activity @ 20 nM IgG / [AU/mM IgG]	Tagg UNCLE [°C] >65°C = OK
TPP-29852	1930000	0.00227	1.18E-09	-	-	-
TPP-29850	1240000	0.00387	3.13E-09	-	-	-
TPP-29864	728000	0.00755	1.04E-08	no binding	1.58	66.9
TPP-29865	682000	0.00865	1.27E-08	no binding	-	-
TPP-29846	834000	0.00531	6.37E-09	no binding	1.57	66.2
TPP-29857	436000	0.0058	1.33E-08	no binding	1.73	67.6
TPP-29847	760000	0.00633	8.33E-09	-	-	-
TPP-29856	738000	0.0157	2.13E-08	no binding	2.08	69.8
TPP-29844	1000000	0.0101	1.01E-08	-	-	-
TPP-29849	839000	0.00854	1.02E-08	-	-	-
TPP-29845	1810000	0.0194	1.07E-08	-	-	-
TPP-29843	618000	0.0138	2.23E-08	no binding	1.62	69.9
TPP-29853	679000	0.0158	2.33E-08	no binding	1.66	72.9
TPP-29862	875000	0.0096	1.10E-08	-	-	-
TPP-29854	704000	0.0177	2.52E-08	no binding	2.17	67.2
TPP-29860	743000	0.0178	2.39E-08	no binding	1.24	65.2
TPP-29861	1280000	0.0145	1.13E-08	-	-	-
TPP-29863	683000	0.0162	2.38E-08	no binding	1.01	66.6
TPP-29866	666000	0.0148	2.22E-08	no binding	1.69	67.4
TPP-29848	790000	0.0128	1.62E-08	no binding	-	-
TPP-29858	803000	0.02	2.49E-08	no binding	1.80	67.7
TPP-29855	672000	0.0175	2.61E-08	no binding	1.74	67.4
TPP-26870	675000	0.027	4.00E-08	no binding	1.00	70.0
TPP-26922	383000	0.0352	9.17E-08	no binding	1.87	71.1
TPP-26939	395000	0.0206	5.21E-08	no binding	1.70	65.7

FIG. 13




FIG. 14A

Histone 3 Cleavage
(1 APC:10 Antibody Ratio)




FIG. 14A (continued)




FIG. 14A (continued)

Histone 3 Cleavage
(1 APC:10 Antibody Ratio)




FIG. 14A (continued)

Histone 3 Cleavage
(1 APC:10 Antibody Ratio)




FIG. 14A (continued)
Histone 3 Cleavage
(1 APC:10 Antibody Ratio)




FIG. 14A (continued)
Histone 3 Cleavage
(1 APC:10 Antibody Ratio)




FIG. 14B

	H3 Band Intensity	
	0 min	60 min
TPP-26922	342633.3	251909
TPP-26939	345714.7	251428.3
TPP-29843	333695.5	235631.3
TPP-29844	322054.8	200035
TPP-29845	331525	211881.3
TPP-29846	329407.8	231111.3
TPP-29847	336344	225818.7
TPP-29848	350595	141066.7
TPP-29849	345365.5	204148.7
TPP-29850	377189.5	229388.7
TPP-29851	388140.2	258082.3
TPP-29852	381755.7	227780.7
TPP-29853	352819.7	233914
TPP-29854	370552.2	281745
TPP-29855	360891.5	253049
TPP-29856	325071	235062.7
TPP-29857	331262.2	252932.3
TPP-29858	325115	248677.7
TPP-29860	322676.5	201865
TPP-29861	321151.8	237945.3
TPP-29863	330800.7	225057
TPP-29864	330402.2	253904.3
TPP-29865	340089.7	238529.7
TPP-29866	334653.2	225337.3
No Ab	314078.5	214661.3
TPP-26870 (ref)	310918.5	214334

FIG. 15

Ab	T1/2 (minutes; mean)	SD	significant	p value (vs TPP2870 by ANOVA)
TPP26922	89.64	4.187	ns	0.9429
TPP26939	102.9	5.504	ns	0.9994
TPP29843	105.3	3.828	ns	0.9996
TPP29844	137.1	11.39	ns	0.779
TPP29845	104	2.551	ns	0.9994
TPP29846	169.6	26.67	*	0.017
TPP29847	132.1	17.3	ns	0.9425
TPP29848	136.4	16.06	ns	0.8063
TPP29849	186.8	22.9	***	0.0008
TPP29850	190.3	25.76	***	0.0004
TPP29851	89.73	7.408	ns	0.9447
TPP29852	321.8	83.11	****	<0.0001
TPP29853	124.6	19.34	ns	0.9954
TPP29854	146.9	6.757	ns	0.3626
TPP29855	110.7	6.202	ns	>0.9999
TPP29856	109.7	3.147	ns	>0.9999
TPP29857	179.2	18.94	**	0.0031
TPP29858	89.74	4.296	ns	0.9448
TPP29860	85	2.372	ns	0.7958
TPP29861	106.9	2.616	ns	0.9997
TPP29863	92.1	4.997	ns	0.9819
TPP29864	138.6	9.209	ns	0.7158
TPP29865	173.1	6.574	**	0.0071
TPP29866	108	3.361	ns	0.9998
No Ab	33.83	5.241	****	<0.0001
TPP26870	110.8	21.94	Ref	Ref

FIG. 16

Antibody	Anti-coagulation activity	SEAP-PAR1 cleavage	Histone cleavage	Sensitivity to physiological inhibitor	Category	Uses
TPP26870	+	+	-	-	1	Prevents bleeding and increases PAR1 cytoprotection signaling, w/ prolonged APC activity
TPP26926	+	+	-	-		
TPP26935	+	+	-	-		
TPP26874	+	+	-	-		
TPP26920	+	+	-	+	2	Prevents bleeding and increases PAR1 cytoprotection signaling, w/ shortened APC activity
TPP26918	+	-	-	+	3	Prevents bleeding, w/ shortened APC activity
TPP26873	+	ND	-	ND	-	Prevents bleeding
TPP26864	+	ND	-	ND	-	Prevents bleeding
TPP26882	-	+	-	+	4	Increases PAR1 cytoprotection signaling, w/ shortened APC activity
TPP26924	-	+	-	-	5	Increases PAR1 cytoprotection signaling, w/ prolonged APC activity
TPP26869	-	+	-	-		
TPP26871	-	+	-	-		
TPP26921	-	+	-	-		
TPP26862	-	-	+	-	6	Reduces histone cytotoxicity, w/ prolonged APC activity
TPP26863	-	-	=	ND	-	Reduces histone cytotoxicity
TPP26934	-	-	-	-	7	Prolongs APC activity
TPP26925	-	-	-	-		
TPP26872	-	-	-	-		
TPP26894	-	-	-	-		

FIG. 17

Antibody	Anticoagulation activity	Histone cleavage	Sensitivity to physiological inhibitor	Category	Uses
TPP-29857	+	-	-	1	Prevents bleeding, w/ prolonged APC activity
TPP-29854	+	-	-		
TPP-29864	+	-	-		
TPP-29865	+	-	-		
TPP-29856	+	-	=		
TPP-29861	+	-	=		
TPP-29843	+	-	=		
TPP-29855	+	-	=	2	Prevents bleeding, w/ shortened APC activity
TPP-29858	+	-	+		
TPP-29847	+	+	-	3	Prevents bleeding, reduces histone cytotoxicity, w/ prolonged APC activity
TPP-29848	+	+	-		
TPP-29849	+	+	-		
TPP-29850	+	+	-		
TPP-29852	+	+	-		
TPP-29853	+	+	-		
TPP-29845	+	+	=		
TPP-29860	+	+	+	4	Prevents bleeding, reduces histone cytotoxicity, w/ shortened APC activity
TPP-29846	-	-	-	5	Prolongs APC activity
TPP-26939	-	-	=	6	
TPP-26922	-	-	+	7	Shortens APC activity
TPP-29863	-	+	-	8	Reduces histone cytotoxicity, w/ prolonged APC activity
TPP-29844	-	+	-	9	
TPP-29866	-	+	=	10	Reduces histone cytotoxicity, w/ shortened APC activity
TPP-29851	-	+	+	11	
TPP-24727 (ref)	-	+	+	-	-

FIG. 18




FIG. 19

	ID	Immunogenicity Score (by T20 Algorithm)	Expression Level (Average)	Expression Level (SD)	k _a [1/Ms]	k _d [1/s]	K _D [M]
Reference	TPP-24727	82.26897	44.6	3.5	3.16E+05	1.42E-02	4.48E-08
Improved	TPP-24737	88.07697	47.8	3.1	3.55E+09	4.44E+01	1.25E-08
	TPP-24738	89.74797	33.5	13.0	4.95E+10	8.96E+01	1.81E-09
	TPP-24739	78.03427	22.9	1.8	1.22E+06	9.00E-04	7.37E-10
	TPP-24740	83.15137	57.7	19.2	2.75E+05	1.66E-02	6.05E-08
	TPP-24743	78.67527	26.6	13.7	2.43E+06	4.23E-04	1.74E-10
	TPP-24744	82.26897	22.0	3.4	5.04E+08	1.15E+01	2.28E-08
Suboptimal	TPP-24745	87.22227	6.0	0.1	1.99E+06	1.52E-01	7.64E-08
	TPP-24750	89.74797	38.0	3.9	4.49E+03	5.94E-02	1.32E-05
	TPP-24766	91.42867	33.6	2.5	2.76E+03	8.20E-02	2.97E-05
	TPP-24769	86.36757	0.9	0.6	no binding	no binding	no binding
	TPP-24777	88.11977	9.8	0.8	5.12E+05	1.61E-02	3.14E-08
	TPP-24815	79.10267	3.2	0.4	no binding	no binding	no binding
OMRF	HAPC14	77.54	-	-	-	-	-
	HAPC14-3	77.28817	-	-	-	-	-
	HAPC14-6	77.28817	-	-	-	-	-

FIG. 20

	ID	Immunogenicity Score (by T20 Algorithm)	Expression Level (Average)	Expression Level (SD)	k _a [1/Ms]	k _d [1/s]	K _D [M]
Reference	TPP-24727	71.17127	44.6	3.5	3.16E+05	1.42E-02	4.48E-08
Improved	TPP-24827	72.34237	68.8	8.2	3.53E+05	1.12E-02	3.17E-08
	TPP-24829	74.36947	77.9	12.9	3.37E+05	1.05E-02	3.13E-08
	TPP-24843	74.27937	65.0	10.9	3.14E+05	1.53E-02	4.86E-08
	TPP-24845	75.81087	88.4	7.1	2.69E+05	1.46E-02	5.40E-08
	TPP-24851	71.12617	44.3	9.5	3.15E+05	1.57E-02	4.98E-08
	TPP-24853	76.80187	68.1	0.4	2.86E+05	1.47E-02	5.15E-08
	TPP-24861	82.07217	34.7	0.3	4.11E+05	9.89E-03	2.41E-08
	TPP-24869	84.63967	26.7	1.8	3.96E+05	9.57E-03	2.42E-08
	TPP-24893	77.43247	60.9	2.9	3.38E+05	9.68E-03	2.86E-08
	TPP-24901	76.48657	37.2	1.8	3.51E+05	9.44E-03	2.69E-08
	TPP-24907	77.38747	60.1	6.6	3.06E+05	1.41E-02	4.59E-08
	TPP-24909	79.14417	44.5	3.6	3.14E+05	1.45E-02	4.62E-08
Suboptimal	TPP-24917	77.88297	21.6	3.7	3.12E+05	1.39E-02	4.46E-08
	TPP-24824	72.43247	58.3	17.2	no binding	no binding	no binding
	TPP-24833	73.46857	5.9	0.9	2.99E+05	1.46E-02	4.90E-08
	TPP-24841	74.45957	9.3	1.6	2.18E+05	2.03E-02	9.32E-08
	TPP-24847	69.68477	2.4	0.1	2.66E+05	2.27E-02	8.55E-08
	TPP-24863	75.9916	0.7	0.0	no binding	no binding	no binding
	TPP-24864	78.46857	0.8	0.1	no binding	no binding	no binding
	TPP-24871	74.41447	0.6	0.0	no binding	no binding	no binding
	TPP-24875	76.89197	1.6	0.4	3.90E+05	1.86E-02	4.77E-08
	TPP-24888	73.24327	53.9	10.5	no binding	no binding	no binding
	TPP-24897	74.14417	1.3	0.1	3.16E+05	1.52E-02	4.79E-08
	TPP-24910	78.64867	61.4	12.0	no binding	no binding	no binding
OMRF	TPP-24911	74.77487	0.9	0.5	7.89E+05	3.41E-02	4.32E-08
	TPP-24913	75.58567	1.2	0.2	2.82E+05	2.41E-02	8.56E-08
	HAPC14	83.46857	-	-	-	-	-
	HAPC14-3	82.43247	-	-	-	-	-
	HAPC14-6	83.37847	-	-	-	-	-